On track to define optimal dosing interval and advance manufacturing scale up of REYOBIQ for pivotal trial readiness in late ...

CG Oncology develops cretostimogene via rolling BLA, phase 3 PIVOT-006 data in 1H 2026, and $680M cash into 2028. Find out ...

A Type B meeting between the FDA and Plus Therapeutics offered clarity and direction for the next steps in development of ...

Dr Eliane Bodanese, an engineering lecturer at Queen Mary University, was twice rejected for a promotion which was instead ...

Epicrispr Reports Early Clinical Activity and Favorable Safety Profile in First-in-Human Epigenetic Editing Study for FSHD ...

The ISPOR Glasgow panel conveyed a constructive, forward looking mood: JCA can work – and work better over time – if ...

DCN Dx, a specialist in diagnostics development, manufacturing, regulatory consulting, and clinical research, today announced the launch of a new prospective biospecimen collections offering, ...

Novel immunotherapy combination regimen brings together two complementary therapies to improve outcomes for people living with multiple myeloma as early as second line1 ...

A simple, speedy single-slope ADC with a biphasic conversion cycle and a decent accuracy. Read on to learn more!

A positive top-line readout from a phase 3 trial has emboldened Incyte to seek the FDA’s blessing for the company’s Monjuvi ...

Both Phase 3 trials met all primary and secondary endpoints with high statistical significance in patients with moderate-to-severe plaque ...